Feb 23, 2022
Immutep to Present at Healthcare Investor Conferences
Feb 17, 2022
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
Feb 11, 2022
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Jan 31, 2022
Immutep to Present at February Investor Conferences
Jan 24, 2022
Immutep Quarterly Activities Report
Dec 15, 2021
Immutep Advances IMP761 Manufacturing
Dec 01, 2021
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Nov 19, 2021
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
Nov 14, 2021
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor
Nov 08, 2021
Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
